CSL Ltd

Common Name
CSL
Country
Australia
Sector
Healthcare
Industry
Biotechnology
Employees
32,698
Ticker
CSL
Exchange
ASX
Description
CSL Limited is a leading biotechnology company specializing in the research, development, manufacturing, and marketing of innovative biopharmaceutical products. The company's core activities focus on ...

Financial Statements of CSL

Below are the financial statements of CSL, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in billions of USD20242023
Sales and service revenue
14.26a
12.78a
Influenza pandemic facility reservation fees
0.17a
0.16a
Royalties and license revenue
0.26a
0.24a
Other income
0.11a
0.14a
Total operating revenue
14.8a
13.31a
Cost of sales
-7.13a
-6.49a
Gross profit
7.67a
6.83a
Research and development expenses
-1.43a
-1.27a
Selling and marketing expenses
-1.57a
-1.48a
General and administration expenses
-0.86a
-1.01a
Total expenses
-3.86a
-3.76a
Operating profit (EBIT)
3.81a
3.07a
Finance costs
-0.48a
-0.44a
Finance income
0.04a
0.04a
Profit before income tax expense
3.38a
2.66a
Income tax expense
-0.66a
-0.42a
Net profit for the year
2.71a
2.24a
Net profit for the year attributable to:
2.71a
2.24a
Shareholders of CSL Limited
2.64a
2.19a
Non-controlling interests
0.07a
0.05a
Download Data

Verified Sources Behind CSL’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CSL’s data sources below and access millions more through our Disclosure Search.

a. CSL's Annual Report 2024
a. CSL's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?